Clinical Trial Update: Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial update for Crisaborole in Chinese and Japanese children aged ≥2 with mild to moderate atopic dermatitis completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Crisaborole (crisaborole)

Snippet

Sponsor: Pfizer | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2022-05-02